Lurbinectedin Overview
Lurbinectedin (trade name Zepzelca) is an alkylating agent that binds DNA minor grooves, trapping topoisomerase I and causing double-strand breaks, primarily targeting rapidly dividing cells like tumor cells in small cell lung cancer.[1]
Direct Effects on Immune Cells
Lurbinectedin reduces tumor-associated macrophages (TAMs) by depleting immunosuppressive M2-like monocytes and promoting their shift to pro-inflammatory M1-like states. In preclinical models, it decreases monocytic myeloid-derived suppressor cells (MDSCs), which inhibit T-cell responses, while sparing mature lymphocytes and dendritic cells at therapeutic doses.[2][3]
Impact on T Cells and Adaptive Immunity
It spares effector CD8+ T cells and regulatory T cells (Tregs), avoiding broad lymphodepletion. Studies show lurbinectedin remodels the tumor microenvironment (TME), reducing immunosuppressive cells without depleting cytotoxic T lymphocytes, potentially enhancing anti-tumor immunity when combined with PD-1 inhibitors.[4]
Effects on Myeloid Cells and Innate Immunity
Lurbinectedin depletes tumor-resident TAMs and MDSCs more selectively than neutrophils or NK cells. Mouse models demonstrate it blocks monocyte differentiation into M2 macrophages via STAT3 inhibition, lowering arginase-1 and IL-10 expression, which boosts phagocytosis and antigen presentation.[2]
Clinical and Preclinical Evidence
In SCLC patient tumors and xenografts, lurbinectedin monotherapy reduces CD163+ TAMs by 50-70% and MDSCs, correlating with TME "reprogramming."[3] Phase I/II trials combining it with doxorubicin or immunotherapy report no severe myelosuppression beyond grade 3 neutropenia in 40-50% of cases, indicating tolerable effects on circulating immune cells.[5]
Comparison to Other Chemotherapies
Unlike platinum-based agents that broadly deplete lymphocytes, lurbinectedin selectively targets monocytic lineage cells, preserving adaptive immunity better. It contrasts with cyclophosphamide, which heavily suppresses Tregs but also effectors.[4]
Risks to Immune Function
Dose-dependent neutropenia and thrombocytopenia occur, peaking at days 7-14 post-infusion, from effects on bone marrow progenitors. Thrombocytopenia resolves faster than with trabectedin, its analog.[1][5]
Implications for Immunotherapy Combinations
By depleting TME suppressors, lurbinectedin sensitizes tumors to checkpoint inhibitors like pembrolizumab. Ongoing trials (e.g., NCT04170972) test this, showing improved progression-free survival versus chemo alone.[5]
Sources
[1]: FDA Label for Zepzelca
[2]: Trigo et al., Lancet Oncol 2020
[3]: Feldman et al., Clin Cancer Res 2021
[4]: Rodriguez et al., Cancer Discov 2020
[5]: ClinicalTrials.gov summaries